Heart drug trial seeks safer dose for millions
NCT ID NCT07273994
Summary
This study is testing whether a lower dose of the heart rhythm drug amiodarone (100 mg/day) works as well as the standard dose (200 mg/day) to keep the heart in a normal rhythm after treatment for persistent atrial fibrillation. It aims to see if the lower dose can control the condition while causing fewer side effects. The trial will follow 312 patients for 12-18 months to compare the two doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital de la Santa Creu i Sant Pau
RECRUITINGBarcelona, 08025, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.